MRNA spotlight — 2026-09-25
MRNA is currently trading near its 52-week high at $195.26, just shy of the peak of $198.28. Over the past month, the stock has seen a significant return of 30.47%, and over the last three months, it has surged by an impressive 190.26%.…
Key figures
Data as of Sep 25, 2026- MRNA last close
- $195.26
- MRNA change vs prior close
- 0.23%
- MRNA market cap
- $72.88B
MRNA is currently trading near its 52-week high at $195.26¹, just shy of the peak of $198.28. Over the past month, the stock has seen a significant return of 30.47%², and over the last three months, it has surged by an impressive 190.26%³. However, despite this strong performance, MRNA's recent earnings per share (EPS) was -1.97⁴, indicating that the company is not currently profitable on a quarterly basis.
The stock’s positive momentum is further supported by two recent positive news sentiments, with headlines like "Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate" and "3 Bullish Setups for the Week Ahead"⁵. MRNA's market capitalization stands at $72.88B⁶, reflecting its significant presence in the biotech sector.
The company’s revenue was reported at $145.00M⁷, and it has been climbing steadily within its 52-week trading range, currently sitting at 98.3% of that range⁸. Despite these positive indicators, the lack of profitability adds a layer of complexity to its valuation multiples.
Educational tool. Not investment advice. This article was produced with automated assistance and reviewed before publishing.